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Diagnosissystem is the major pathway for intracellular protein degradation and is also
deeply involved in the regulation of most basic cellular processes. Its proteolytic core, the 20S proteasome,
has found to be attached also to the cell plasma membrane and certain observations are interpreted as to
suggest that they may be released into the extracellular medium, e.g. in the alveolar lining ﬂuid, epididymal
ﬂuid and possibly during the acrosome reaction. Proteasomes have also been detected in normal human
blood plasma and designated circulating proteasomes; these have a comparatively low speciﬁc activity, a
distinct pattern of subtypes and their exact origin is still enigmatic. In patients suffering from autoimmune
diseases, malignant myeloproliferative syndromes, multiple myeloma, acute and chronic lymphatic
leukaemia, solid tumour, sepsis or trauma, respectively, the concentration of circulating proteasomes has
been found to be elevated, to correlate with the disease state and has even prognostic signiﬁcance. Similarly,
ubiquitin has been discovered as a normal component of human blood and seminal plasma and in ovarian
follicular ﬂuid. Increased concentrations were measured in diverse pathological situations, not only in blood
plasma but also in cerebrospinal ﬂuid, where it may have neuroprotective effects. As defective spermatozoa
are covered with ubiquitin in the epididymal ﬂuid, extracellular ubiquitination is proposed to be a
mechanism for quality control in spermatogenesis. Growing evidence exists also for a participation of
extracellular proteasomes and ubiquitin in the fertilization process.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe increasing interest in the mechanisms of protein degradation
during the last four to ﬁve decades led to the realization that there
may be as many proteases as there are proteins in an organism.
Although this is certainly not the case, the considerable heterogeneity
with regard to the protease pool in different cells and tissues was
probably suggestive of this idea [1]. However, since the discovery of
the ubiquitin–proteasome system (UPS), it is known that each
eukaryotic cell contains basic degradation machinery, the proteolytic
core facility of which is the cylinder-like 20S proteasome. This is built
up by four stacked seven-membered rings; the two outer rings are
composed of seven different α-subunits, the two inner of seven
different β-subunits. Three β-subunits (β1, β2, and β5) posses an N-
terminal threonine residue each forming a peptide-bond hydrolysing
catalytic site, all oriented into the inner central chamber of the
proteasome barrel and with different substrate speciﬁcity, namely
chymotrypsin-, trypsin-, and caspase-like activity, respectively [2].
Under the inﬂuence of the cytokine interferon-γ standard-protea-
somes can be replaced by immuno-proteasomes that have been, Charité-Universitätsmedizin-
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l rights reserved.incorporated instead of the three standard β-subunits the immuno-
subunits β1i (LMP2), β2i (MECL1) and β5i (LMP7) and thus complete
special tasks for antigen processing [3].
All proteins are broken down after their distinct life-time and
therefore have to bemarked for commitment to degradation. For most
intracellular proteins this is managed by their conjugationwith a poly-
ubiquitin chain, a process implying three steps: the ATP-dependent
activation of ubiquitin by a ubiquitin-activating enzyme (E1), transfer
of activated ubiquitin to a ubiquitin-conjugating enzyme (E2) and
then forming an isopeptide bond between ubiquitin and the substrate
protein catalysed by a ubiquitin–ligase (E3). The process is repeated
several times with the aim to build up a poly-ubiquitin chain by inter-
ubiquitin linkages [4]. The poly-ubiquitinated protein is then
recognized and bound by a 19S regulator complex that is associated
to the α-subunit ring of the 20S proteasome thus having formed the
26S proteasome. After binding to the 19S regulator the ubiquitin chain
is cleaved off the ubiquitinated substrate protein, the protein is
unfolded and then translocated into the central chamber of the 20S
proteasome, where it is degraded. The ubiquitin–proteasome system
is not only responsible for the breakdown of outlived proteins, but also
for regulation of basic cellular processes including cell cycling and
proliferation, gene transcription and differentiation, apoptosis, signal
transduction, antigen processing and many others [5]. So, it is not
unexpected that impairment of the UPS has pathological conse-
quences or rather the UPS is a therapeutic target [6–10].
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properties of two essential components of the UPS, namely the
proteasome and ubiquitin, existing as constituents of extracellular
ﬂuids as well as of blood plasma, and it delineates their possible
signiﬁcance for diagnosis and outcome of various malignant and non-
malignant diseases.
2. Evidence for the association of proteasomes to the cell
plasma membrane
The 20S proteasomewas originally discovered as a hollow cylinder
protein associated to human erythrocyte membranes and designated
cylindrin [11–14]. Later on it was also isolated from the cytoplasm of
erythrocytes [15]. Today it is known that the major part of
proteasomes is located within the cytoplasmic and nuclear compart-
ments while only a minor fraction is associated to membranes [16].
When the major lipopolysaccharide (LPS) component of gram-
negative bacteria was added to a membrane preparation from murine
macrophages, it was observed to be speciﬁcally bound by 20S
proteasomes that are attached to the membranes [17]. The endoplas-
mic reticulum (ER) membrane was shown to be the platform for
proteasome biogenesis [18] and ER membrane-associated matured
proteasomes have been puriﬁed and characterized from rat liver cells
and HeLa cells [19–21]. A member of the immunophilin family of
proteins, FK506-binding protein 38, that resides in the ER and
mitochondrial outer membrane was suggested to anchor 26S protea-
somes at membranes [22]. In vitro proteasomes have been shown to
bind to phospholipid monolayers with a preferred orientation [23]
and in vivo they may even be partially buried within the membrane
because a certain fraction of ER-associated proteasomes was found to
be resistant to degradation by trypsin [19]. The presence of
proteasomes at the surface of cell membrane was reported by Bureau
and co-workers, who detected proteasomes at the cell surface of a
non-permeabilized human leukaemic cell line (U937) and of human T
and B lymphocytes by use of proteasome subunit-speciﬁc antibodies
and ﬂow cytometry [24,25]. According to these investigations the
pattern of proteasomal epitopes detectable at the surface of the cells
changed depending on their stage of differentiation after treatment
with phorbol-myristate ester, retinoic acid or vitamin D3 and their
cluster of differentiation, respectively. The authors could not detect
proteasomes in the culture medium of the leukaemic cells [25], but
nevertheless speculated that the enzymes are released somehow into
the extracellular medium and may function as paracrine factors [24].
Several investigations by Sawada and co-workers presented
evidence that proteasomes participate in the fertilization process in
various marine invertebrates [26–28]. Morales et al. reported that
human sperm proteasome is also implicated in acrosomal exocytosis
[29]. By using Triton-X-114 for partitioning of human sperm extracts
into membrane-bound and soluble proteins, the authors found 80% of
proteasome activity in a membrane-bound form. After in vivo
biotinylation of sperms and subsequent isolation of sperm mem-
branes, more than 80% of the proteasome activity could be removed by
avidin bound to agarose beads, indicating that the major part of
proteasome activity is associated with the plasmamembrane and only
a minor part with intracellular membranes of spermatocytes. Since
these proteasomes could be labelled with proteasome-speciﬁc
antibodies without permeabilization of the sperms, the epitopes
seem to be accessible on the surface of sperm heads [30]. These data
and similar results obtained with mouse spermatocytes [31] corro-
borated earlier ﬁndings on detection, isolation and identiﬁcation of
proteasomes at membranes of human spermatozoa [32,33]. Protea-
somes thus extracellularly exposed are supposed to participate in the
acrosome reaction [34,35], penetration of the zona pellucida and
fertilization [36]. The detection of a ubiquitin-C-terminal hydrolase at
the surface of a sperm acrosome [37] and the selective proteasomal
degradation of a ubiquitinated zona pellucida glycoprotein duringfertilization [38] corroborate this suggestion. Reaction of these
surface-exposed proteasomes with proteasome auto-antibodies has
been suggested to be causative for autoimmune infertility in man [32].
By means of immunoﬂuorescence microscopy Sutovsky et al. showed
that proteasomes in boar sperm acrosome contain inducible immuno-
subunits β1i and β2i [36], a ﬁnding recently supported by proteomic
analysis of bovine spermatozoa [39] Tengowski et al. reported about a
differential expression of genes encoding constitutive and inducible
20S proteasomes subunits in rat testis and epididymis [40]. Although
proteasomes may be released from sperm caps during the acrosome
reaction no clear evidence for such a process is presented so far in the
literature. Nevertheless, all these data indicate that proteasomes are
bound to the plasma membrane and may be even partly exposed to
the cell surface.
3. Extracellular proteasomes
The outer-surface of the lung is coated by alveolar ﬂuid called
epithelial lining ﬂuid. By using the technique of bronchoalveolar
lavage (BAL) [41] Sixt et al. [42] collected this extracellular ﬂuid and
measured in these ﬂuid samples considerable proteolytic activity that
hydrolysed proteasome-speciﬁc ﬂuorogenic peptide-substrates and
was inhibited by the proteasome-speciﬁc inhibitor epoxomicin.
Extraction of this proteolytic activity by gel ﬁltration revealed a
660 kD proteinase that reacted with antibodies to several proteasomal
α- and β-subunits. Additionally, mass spectrometric analysis showed
the presence of several proteasome α-subunits within the enzyme
preparation, indicating that proteasomes are a component of the
extracellular alveolar ﬂuid. A critical question was whether these
proteasomes are present within the alveolar ﬂuid or originate from
cells within the ﬂuid that were damaged during BAL. Depending on
the substrate used 94–62% of the proteolytic activity was found in the
supernatant after precipitation of cellular material by centrifugation.
Interestingly, there was neither a positive correlation between cell
lysis as measured by LDH activity released during centrifugation of the
BAL ﬂuid and proteolytic activity measured in the supernatant, nor
between the number of cells stainable with trypan blue in the
centrifugation pellet and the proteolytic activity in the supernatant
[42]. These data exclude that cell damage is a major source for the
proteasomes found in the BAL ﬂuid. The extracellular proteasome
exhibited a high cleavage rate of albumin that was ATP- and ubiquitin-
independent and inhibited by epoxomicin [42].
Thus, by catalysing alveolar protein degradation theproteasomemay
possibly assist in maintenance of a low intra-alveolar oncotic pressure.
Since the alveolar albumin concentration often increases in lung
diseases [43], it was of interest to assess the alveolar proteasomal
albumin degradation in lung diseases. The acute respiratory distress
syndrome (ARDS) is a clinical syndrome characterized by inﬂammatory
pulmonary edema, hyaline membranes, diffuse endothelial and epithe-
lial injury and ﬁbrosis [44]. Despite a signiﬁcantly higher proteasome
concentration in the alveolar space of ARDS patients compared to
subjects without lung diseases (1069±1194 ng/ml vs. 60±49 ng/ml),
ARDS patients had a signiﬁcantly lower extracellular alveolar protea-
some activity as compared to control (Sixt, U.S., unpublished data).
Whether this reduced activity is a result from or an explanation for the
high concentration of albumin found in the extracellular alveolar
space of patients suffering from severe ARDS [45] awaits further
investigations.
4. Circulating proteasomes
Due to the mutual exchange between blood and alveolar ﬂuid the
acellular components of BAL ﬂuid are believed to originate not only
from the lung but also from the blood. Therefore it is not a surprise
that the concentration of proteasomes in blood plasmawas also found
to be higher in ARDS patients than in subjects without lung disease,
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blood plasma and BAL ﬂuid (Sixt, U.S., unpublished data). By using the
enzyme-linked immunosorbent assays technique (ELISA) Wada et al.
were the ﬁrst to detect 20S proteasomes in human serum [46] that
nowadays are generally designated ‘circulating’ proteasomes (c-
proteasomes). As shown by electron microscopy puriﬁed c-protea-
somes are intact 20S proteasome particles that exhibit ﬂuorogenic
peptide hydrolysing activity and are inhibited by lactacystin [47].
Additionally, proteins reacting with proteasome-subunit antibodies
were detected in fractions containing low-molecular weight material,
when serum was fractionated by sucrose-gradient fractionation,
indicating that blood plasma may also contain a certain amount of
disintegrated proteasomes [48].
As it was known since the beginning of the last decade that the
generation of proteasomes is enhanced in various malignant hema-
topoietic cell lines [49], Wada et al. measured the proteasome
concentrations in serum samples of patients with hematologic
malignancies and found a positive correlation between proteasome
concentration and the tumour burden of the patients [46]. In patients
suffering from acute leukaemia, Non-Hodgkin' lymphoma and multi-
ple myeloma (MM) the elevated serum concentration of proteasomes
were signiﬁcantly lowered after complete remission by chemotherapy
but remained unaltered or even increased in patients with no
remission [46]. Lavabre-Bertrand et al. [50] also measured proteasome
levels in blood plasma from patients with malignant hemopoietic
disorders and found considerably elevated concentrations of c-
proteasomes in chronic myeloproliferative syndrome and myelodys-
plastic syndrome, whereas in patients with acute myelocytic leukae-
mia the concentrations was not different from non-diseased control
persons. The concentrations of c-proteasomes were statistically even
lower in patients with lymphoid hemopoietic malignancies like
chronic lymphatic leukaemia (CLL), MM and Non-Hodgkin-lym-
phoma, except if the disease was in an aggressive phase that was
reﬂected in signiﬁcantly higher levels of c-proteasomes.
Interdependency between the stage of malignancy and the level of
c-proteasomes was also detected in patients with metastatic malig-
nant melanoma [51]. While stages I and II were not signiﬁcantly
different from healthy volunteers, patients with stages III and IV
malignant melanomas partially suffering from distant metastases, had
up to 4.5 times higher concentrations of c-proteasomes as compared
to sera of control persons.
In their investigation Lavabre-Bertrand et al. [50] detected
signiﬁcantly elevated concentrations of circulating proteasomes also
in patients with different solid tumours (carcinoma of breast, stomach,
kidney, colon, lung, testes and liver, respectively). This observation
was supported by other investigators [52]. But signiﬁcantly increased
levels of c-proteasomes were also found in non-cancerous diseases,
for instance in patients suffering from liver diseases like liver cirrhosis,
acute or chronic hepatitis and fatty liver [46]. This was also clearly
shown in septic and in trauma patients, who had 15-fold or even
higher concentrations of c-proteasomes as compared to controls,
whereas the level in patients who underwent uncomplicated
abdominal surgery the concentration was only twice that of healthy
subjects [53]. In a perioperative follow-up of patients undergoing
thoracoscopic thymectomy a biphasic alteration of c-proteasomes was
observed with a decrease during the surgical treatment and a post-
operative increase [48]. A similar observationwasmadewith coronary
artery bypass graft patients [54]. Concentrations of c-proteasomes
were also measured in patients with various autoimmune diseases
and their levels found to be elevated up to 20-fold especially in
patients with systemic and organ-speciﬁc autoimmune diseases,
among others autoimmune myositis, Jo-1 syndrome, systemic lupus
erythematosus, primary Sjögren syndrome, rheumatoid arthritis,
vasculitis, systemic scleroderma, autoimmune hepatitis, whereas
patients suffering from myasthenia gravis exhibited control levels
[48]. Similar to the data obtained with cancer patients [46,50,51] thelevels of c-proteasomes were related to the disease activity, since
according to follow-up studies with patients suffering from rheuma-
toid arthritis and systemic lupus erythematosus clinical improvement
went always along with a reduction if not normalisation of the
concentration of c-proteasomes [48].
5. Clinical signiﬁcance of circulating proteasomes
The relationship between clinical state and concentration of
c-proteasomes that was found in patients with systemic lupus
erythematosus, rheumatoid arthritis [48] and hematologic malig-
nancies [46] induced Jakob et al. to scrutinize c-proteasome levels in
patients with multiple myeloma as well as their alterations in
dependence on different forms of chemotherapeutic treatment [55].
In comparison to healthy controls c-proteasome levels were
signiﬁcantly increased in newly diagnosed and untreated patients
suffering from monoclonal gammopathies with undetermined sig-
niﬁcance, from smoldering, asymptomatic and from active multiple
myeloma. In agreement with observations in other studies [46,48]
patients with active MM, who positively responded on standard- or
high-dose chemotherapy, had signiﬁcantly lower post-treatment c-
proteasome levels, an effect not observed in non-responders.
However, even more interesting was that c-proteasome concentra-
tions lower than the median (744 ng/ml) measured in all active MM
patients predicted an overall longer survival than those with values
above 744 ng/ml serum [55].
Although these data show that the concentration of circulating
proteasomes can be used as an independent prognostic factor for
survival in MM patients and probably also for other diseases [56], a
practical problem arises from the fact that the absolute concentra-
tions of c-proteasomes published are not always in the same order,
since different laboratories use different ELISA techniques for
quantiﬁcation of c-proteasomes. While levels in normal subjects
were b400 ng/ml serum in one group of investigators [46,48,55],
concentrations between 2100 and 2400 ng/ml serum of healthy
control persons were measured in other laboratories [50–53]. To
overcome such problems Ma et al. [56] developed a method to
determine the three proteolytic activities of proteasomes in serum as
an alternative to quantifying the c-proteasome concentration by
ELISA techniques. More details of this methodology would be helpful
in the interest of a wider application, e.g. what were the ﬁnal
substrate concentrations used and why the plasma had to be activated
by means of 1% SDS or 1% Tween-20, especially since already 1% SDS
was shown to inhibit 20S proteasomes completely [57]. According to
these investigations the hydrolytic activities measured by use of
ﬂuorogenic tripeptide-substrates were in the same order as the
activities in white blood cell lysates and the chymotrypsin-like
activity was inhibited by YU-101, a synthetic tetrapeptide epoxyke-
tone known to inhibit the proteasome [58]. Although not in keeping
with unaltered concentrations of c-proteasomes in CLL patients [50],
Ma et al. [56] found that the three proteasome activities were
signiﬁcantly elevated in plasma from patients with chronic lymphatic
leukaemia (CLL) as compared to controls, but the activities were not
affected by treatment of the patients. Nevertheless, the caspase-like
activity and also to a certain degree the chymotrypsin-like activity
measured in the activated plasma from CLL patients are predictors of
survival: elevated activities (N1.32 pmol Z-LLE-MCA hydrolysis/s/ml
plasma and N1.28 pmol Suc-LLVY-MCA hydrolysis/s/ml plasma)
correlate with shorter survival; surprisingly, the trypsin-like activity
had no predictive value [56].
6. The origin of c-proteasomes
When the concentration and/or the activity of c-proteasomes have
a prognostic value for the course of diseases and even survival of a
patient, knowledge about the origin of these blood plasma
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detailed above pathophysiological conditions with rapidly proliferat-
ing cells and neoplastic tissue go very often along with signiﬁcantly
elevated levels of c-proteasomes. The proteasome as the central part
of the UPS is a major regulator of cell proliferation [59] and enhanced
expression of proteasomes has been observed in various cancer cell
lines [49,60,61]. Therefore,Wada et al. speculated that increased levels
of c-proteasomes may be due to their secretion from tumour cells or
the enzyme is released from disintegrating tumour cells [46]. Since
these are two completely differentmechanisms thatmay contribute to
the phenomenon of the existence of c-proteasomes, they should be
discernible from each other. If tumour cells die by other than apoptotic
mechanisms, e.g. by mechanical destruction due to their large size, by
cell necrosis or by T-cell- or macrophage-induced cytolysis, all sorts of
cell componentsmay be released into the extracellular space, amongst
others 20S proteasomes. A commonly used marker for this type of
cytolysis is the cytoplasmic enzyme lactate dehydrogenase (LDH) the
concentration of which was measured in parallel to c-proteasomes in
some of the studies mentioned above. Lavabre-Bertrand et al. [50]
calculated the blood plasma LDH/plasma c-proteasome correlation for
all (N300) tumour patients inspected in their study and found a
positive correlation between both parameters but with numerous
exceptions. A poor but signiﬁcant correlation was also found in MM
patients [51]. Similarly, hepatocellular carcinoma goes along with a
positive correlation between the activity of serum alanine amino-
transferase (ALT) and c-proteasomes [46]. But proliferation and
cytolysis of malignant cells cannot be the only source for c-
proteasomes, since patients with benign liver diseases like cirrhosis,
chronic hepatitis and fatty liver, respectively, showed also a close
positive correlation between serum ALT activity and c-proteasome
concentration [46]. The post-operative increase of c-proteasome
concentration measured in thymectomy patients [48] may support
the hypothesis that proteasomes originate from injured cells. On the
other hand, the fact that no signiﬁcantly elevated c-proteasome
concentrations were found in patients after abdominal surgery, but in
patients suffering from trauma and sepsis, respectively, induced Roth
et al. [53] to conclude ‘that the immunological activity rather than
cellular damage is causative of the early increased 20S proteasome
levels in sepsis and severe injury’. This opinion seems to be in line
with the ﬁnding that remarkably high c-proteasome concentrations
were found in patients with systemic and non-systemic autoimmune
diseases, like systemic lupus erythematosus (SLE), primary Sjögren's
syndrome (pSS), rheumatoid arthritis, autoimmune myositis, and
autoimmune hepatitis [48]. Circulating proteasomes puriﬁed from
blood plasma of SLE and pSS contain immuno β-subunits suggesting
that they are primarily released from immuno-competent cells.
However, this idea was scrutinized by comparing the subtype-pattern
of proteasomes puriﬁed from monocytes, T-lymphocytes and throm-
bocytes with that of puriﬁed c-proteasomes. Fractionation of 20STable 1
Activities of 20S proteasomes puriﬁed from human plasma and various blood cells
Puriﬁed proteasomes from Speciﬁc activity (pmol/ng protein×min)
Suc-LLVY-MCA Z-LLE-MCA Bz-VGR-MCA
Erythrocytes 5.20 1.9 2.60
Thrombocytes 1.45 0.16 1.14
Monocytes 0.95 0.26 0.64
T-Lymphocytes 2.00 0.26 0.23
Plasmaa 0.26 0.29 0.20
Plasmab 0.026 0.028 0.020
Speciﬁc activities are given as pmol substrate hydrolysis per ng puriﬁed proteasome
per min. Data for proteasomes from erythrocytes, thrombocytes, monocytes and
t-lymphocytes are given in [113] and from blood plasma were calculated on the basis
of the activities given in [56] either pertained to a mean normal concentration of
a220 ng/ml [46,48,55], or of b2200 ng/ml blood plasma [50–53].proteasomes based on their minimal differences in surface-charge has
shown, that standard-proteasomes can be separated from immuno-
proteasomes and intermediate-type proteasomes, the latter contain-
ing both standard- and immuno-subunits at the same time [21,62]. No
similarity of the subtype-pattern of c-proteasomes, neither from
normal subjects nor from patients with SLE and rheumatoid arthritis,
respectively, could be shown with the subtype-patterns of 20S
proteasomes from monocytes, T-lymphocytes and thrombocytes
[47]. On the other hand, all of these proteasome-subtype-patterns
are different from that obtained with 20S proteasomes from
erythrocytes, excluding that c-proteasomes have their origin in red
blood cells disintegrating during blood plasma sampling [47]. This
conclusion is supported by comparing the speciﬁc hydrolytic activities
measured with proteasomes from the different origins, showing that
c-proteasomes have signiﬁcantly lower activities than proteasomes
from erythrocytes and from other white blood cells (Table 1).
7. Mechanisms of cellular proteasome release
It was suggested that c-proteasomes are released into the blood
plasma from apoptotic cells due to an impaired mechanism of
phagocytosis in macrophages [63]. Although this could explain the
elevated concentrations of c-proteasomes measured in patients
suffering from diseases that are going along with increased cell
death, the unusual low speciﬁc activity of c-proteasomes, their
particular subtype-pattern and their relatively constant level cast
some doubt whether this mechanism holds true also in non-diseased
control subjects. No correlation of c-proteasome levels was detected
with gender or age [55]. Some authors mentioned that they have
detected high concentrations of proteasomes in culture supernatants
of leukaemia cells [46,64] and speculated that a special secretion
mechanism may exist in cancer cells [46]. Proteomic based analysis of
the so-called secretome of murine myeloid cells cultured under
serum-free conditions as well as of the human visceral adipose tissue
also revealed the presence of many 20S proteasome subunits. They
were classiﬁed under non-classically secreted proteins [65,66].
Secretion of proteins by ‘classical’ mechanisms is based on the
presence of signal-peptide dependent translocation of newly synthe-
sized proteins into the endoplasmic reticulum and subsequent
transportation by the cis/trans-Golgi apparatus to the plasma
membrane. Proteasomes have never been detected inside of the ER/
Golgi-compartment [67] and thus it is very unlikely that they use this
pathway to leave the cell. But ‘non-classical’, unconventional secretory
routes have been described for export of proteins across the plasma
membrane of mammalian cells, e.g. by means of membrane-resident
transporters or by shedding of plasma membrane-derived exovesicles
[68] as detailed in the next chapter [69,70]. As stated above
proteasomes are associated to the plasma membrane and the latter
mechanism might be responsible for extruding them into the
environment of the cell. Since proteins even larger than the 20S
proteasome (700 kD), like α2-macroglobuline (820 kD) and immu-
noglobuline M (900 kD), were detected in the epithelial lining ﬂuid
[71], transport mechanisms for expulsion of these macromolecules
must be present in the alveolar epithelial cells that may explain the
presence of extracellular alveolar proteasomes [72].
8. Extracellular ubiquitin
Already in 1993 increased blood plasma concentrations of
ubiquitin were measured in patients subjected to hemodialysis [73]
and as compared to healthy control persons ubiquitin was also found
to be elevated in blood plasma of subjects with parasitic and allergic
diseases, respectively [74]. Similarly, increased concentrations of
ubiquitin were found in cerebrospinal ﬂuid of patients suffering
from Creutzfeldt–Jakob disease [75] and from Alzheimer's disease,
respectively [76,77]. However, a discrimination between mono-
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radioimmunoassay detecting exclusively mono-ubiquitin [78]. This
assay allowed to detect and determine the concentrations of mono-
and poly-ubiquitin in serum of healthy human subjects and to
discover that the concentrations of both types of ubiquitin are slightly
elevated in patients suffering from rheumatoid arthritis or subjected
to hemodialysis [79]. Increased systemic levels of extracellular
ubiquitin have also been observed in several very different diseases
like alcohol liver cirrhosis and brain atrophy [80], type 2 diabetes [81],
chronic hemodialysis [82], hairy cell leukaemia [83], sepsis [84] and
severe trauma [85]. Furthermore, in anoxic–ischemic encephalopathy
after cardiopulmonary arrest extracellular ubiquitin was observed in
the cerebrospinal ﬂuid three days after resuscitation and correlated
with outcome [86]. Interestingly, intravenous infusion of ubiquitin
into rats after focal cortical contusion brain injury reduces the
contusion volume and had neuroprotective effects. Also, during
resuscitation from severe trauma intravenous application of ubiquitin
reduced the intravenous ﬂuid required to maintain mean arterial
pressure [85,87]. Similarly, infusion of ubiquitin has been shown to
have beneﬁcial effects on wound healing [88].
These data indicate that cell damage and hemolysis are the major
sources of the increased extracellular ubiquitin concentrations
measured under various pathological conditions, especially poly-
ubiquitin the concentration of which shows positive correlation with
serum ALT, AST and LDH in patients with acute viral hepatitis
[79,84,85,89]. However, these data also suggest that ubiquitin fulﬁls
certain functions in the extracellular space. A similar observation was
published already in 1975, when Goldstein et al. discovered that
extracellular ubiquitin inﬂuences the differentiation of pro-B- and
pro-T-lymphocytes [90]. Other investigators observed that extracel-
lular ubiquitin seems to have pleiotropic effects in hematopoietic cells
[91] like antimicrobial activity [92], induction of apoptosis [83] as well
as inhibition of platelet activities [93], suppression of IgG-induced
proliferative responses in B-cells [94] and inﬂuence on the LPS-
induced production of TNFα in macrophages [95]. Similar to
proteasomes low concentrations of mono-ubiquitin (≈50 ng/ml) and
poly-ubiquitin (≈3–4 ng/ml) were measured also in serum samples of
healthy control subjects [79]. Therefore, one should also consider
active cellular secretion as a source of extracellular ubiquitin [96], an
approach that is corroborated by the fact that ubiquitin was detected
in the secretome of mouse preimplantation embryos [97].
Epididymal epithelial cells form small membrane-enclosed secre-
tory vesicles designated epididymosomes (equivalent to exosomes)
[69] as well as large blebs that are released from the apical surface
membrane, therefore designated apical blebs or aposomes [70]. Both
were shown to extrude cytoplasmic proteins, including ubiquitin [98]
explaining why free mono-ubiquitin was detected in medium of
cultured epididymal epithelia cells [99]. Free ubiquitin was also
detected in human seminal plasma [100] as well as in bovine
preovulatory folicullar ﬂuids [101]. Since defective spermatozoa
have found to be ubiquitinated on their surface [99], surface-
ubiquitination has been interpreted as a quality control mechanism
during sperm development [99,102,103]. Recently, Sutovsky and co-
workers presented evidence by using immuno/Western blotting
techniques that beside of ubiquitin the ubiquitin-activating enzyme
(E1), a ubiquitin carrier enzyme (E2) and a ubiquitin-C-terminal
hydrolase is present in bovine epididymal ﬂuid [104]. By means of the
same technique as well as by measuring and speciﬁcally inhibiting
ﬂuorogenic peptide hydrolytic activity a certain evidence was
obtained that 26S proteasomes are present in the epididymal ﬂuid, a
ﬁnding corroborating data published by Jones [103]. The authors
hypothesize that in case there is also a ubiquitin-conjugating enzyme
(E3) secreted from the epididymal cells, extracellular proteins might
be ubiquitinated and degraded by an extracellular UPS [104] that
performs sperm quality control [102] and control for proteins secreted
by the epididymal epithelial cells [105].9. Conclusion and next frontiers
The overwhelming amount of data collected on the manifold
functions of proteasomes and ubiquitin in the ﬁne-tuned intracellular
protein degradation and its involvement in almost all biochemical
pathways, eclipses the results elaborated on the existence and
signiﬁcance of extracellular proteasomes (that we suggest to designate
e-proteasome in the future) and ubiquitin. Although the shear fact
about their extracellular presence is beyond controversy, their origin
and especially their functions in extracellular ﬂuids and blood plasma
are still enigmatic. Whether the reproductive system due to its special
secretionmechanisms is the exception of the rule that proteasomes and
ubiquitin are proteins working almost exclusively inside of the cell or
whether other cells, e.g. also those forming the alveolar lining, do also
extrude these proteins by peculiar mechanisms has to be thoroughly
investigated. If so, the role of these proteins may not necessarily be
identical with their intracellular function, since many examples are
known for proteins performing multiple, unrelated functions and are
thus designated ‘moonlighting’ proteins [106,107]. This idea can easily
be imagined for ubiquitin that performs posttranslational modiﬁca-
tions of proteins and thus is known to mediate functions other than
committing proteins for their degradation, e.g. regulating the cyto-
plasmic-nuclear trafﬁcking and the endocytic pathway [108–110]. Non-
proteolytic functions have been attributed also to proteasomes [111]
but have been scarcely substantiated experimentally. Although
different models have been proposed for the participation of either a
complete extracellular UPS or just acrosomal-released proteasomes in
the interaction of sperm and ovarian zona pellucida [36], this aspect
may be of importance for treatment of infertility and/or contraceptive
research [102]. Another major task should be to generally establish the
diagnostic impact of the concentration of c-proteasomes especially
with regard to their prognostic signiﬁcance in critically ill patients or
patients suffering from various types of malignant diseases as was also
proposed for proteasome antibodies [112].
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